Teva and Alvotech launch SIMLANDI in US for arthritis
This marks the first biosimilar launched under the strategic partnership between the two companies. SIMLANDI has been approved by the US Food and Drug Administration (FDA) as the
Radar Therapeutics has successfully completed an oversubscribed seed funding round, raising $13.4m for developing smart programmable medicines.